J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
$650m buys the group rights to RemeGen’s RC148.
After Aktis's $318m flotation Eikon is a bigger proposition.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
